John Hutton

Summary

Affiliation: University of York
Country: UK

Publications

  1. ncbi COPD uncovered: an international survey on the impact of chronic obstructive pulmonary disease [COPD] on a working age population
    Monica J Fletcher
    Education for Health, Warwick, UK
    BMC Public Health 11:612. 2011
  2. ncbi Harmonization of evidence requirements for health technology assessment in reimbursement decision making
    John Hutton
    York Health Economics Consortium, University of York, Market Square, Heslington, York, UK
    Int J Technol Assess Health Care 24:511-7. 2008
  3. ncbi Coverage with evidence development: an examination of conceptual and policy issues
    John Hutton
    University of York, York Y010 5DD, UK
    Int J Technol Assess Health Care 23:425-32. 2007
  4. ncbi The feasibility of harmonizing health technology assessments across jurisdictions: a case study of drug eluting stents
    Paul Trueman
    University of York, North Yorkshire, UK
    Int J Technol Assess Health Care 25:455-62. 2009
  5. ncbi Framework for describing and classifying decision-making systems using technology assessment to determine the reimbursement of health technologies (fourth hurdle systems)
    John Hutton
    Department of Health Sciences, University of York, Heslington, UK
    Int J Technol Assess Health Care 22:10-8. 2006
  6. ncbi Cost-effectiveness of oral ibandronate versus IV zoledronic acid or IV pamidronate for bone metastases in patients receiving oral hormonal therapy for breast cancer in the United Kingdom
    Erwin De Cock
    The MEDTAP Institute at UBC, London, UK
    Clin Ther 27:1295-310. 2005
  7. ncbi Selecting methods for the prediction of future events in cost-effectiveness models: a decision-framework and example from the cardiovascular field
    Richard Grieve
    Health Services Research Unit, Department of Public Health and Policy, London School of Hygiene and Tropical Medicine, Keppel Street, London, WC1E 7HT, UK
    Health Policy 64:311-24. 2003
  8. ncbi Regulating the economic evaluation of pharmaceuticals and medical devices: a European perspective
    Richard Cookson
    School of Medicine, Health Policy and Practice, University of East Anglia, Norwich Norfolk, NR4 7TJ, UK
    Health Policy 63:167-78. 2003
  9. ncbi Developing the revised NICE appraisal technical guidance to manufacturers and sponsors: opportunity or threat?
    Rod S Taylor
    Department of Epidemiology and Public Health, University of Birmingham, Birmingham, United Kingdom
    Pharmacoeconomics 20:1031-8. 2002
  10. ncbi Re: Detourney, B. The value of economic modeling studies in the evaluation of treatment strategies for multiple sclerosis. (Editorial) Value Health 2002;5:1-2
    John Hutton
    Value Health 5:114-5. 2002

Collaborators

Detail Information

Publications11

  1. ncbi COPD uncovered: an international survey on the impact of chronic obstructive pulmonary disease [COPD] on a working age population
    Monica J Fletcher
    Education for Health, Warwick, UK
    BMC Public Health 11:612. 2011
    ..The burden of disease is known to be high, though less is known about those of a younger age. The aim of this study was to investigate the wider personal, economic and societal burden of COPD on a cross country working-age cohort...
  2. ncbi Harmonization of evidence requirements for health technology assessment in reimbursement decision making
    John Hutton
    York Health Economics Consortium, University of York, Market Square, Heslington, York, UK
    Int J Technol Assess Health Care 24:511-7. 2008
    ..This study draws on experiences from recent initiatives intended to promote the harmonization of HTA and experience from related fields, particularly regulatory approval of new medical technologies...
  3. ncbi Coverage with evidence development: an examination of conceptual and policy issues
    John Hutton
    University of York, York Y010 5DD, UK
    Int J Technol Assess Health Care 23:425-32. 2007
    ..This study is intended to further the debate on the use of CED as well as highlight areas that warrant further research...
  4. ncbi The feasibility of harmonizing health technology assessments across jurisdictions: a case study of drug eluting stents
    Paul Trueman
    University of York, North Yorkshire, UK
    Int J Technol Assess Health Care 25:455-62. 2009
    ..This study aims to consider four HTAs of drug eluting stents to determine the degree to which the methods adopted, evidence considered, and resulting recommendations diverge...
  5. ncbi Framework for describing and classifying decision-making systems using technology assessment to determine the reimbursement of health technologies (fourth hurdle systems)
    John Hutton
    Department of Health Sciences, University of York, Heslington, UK
    Int J Technol Assess Health Care 22:10-8. 2006
    ..To achieve a better understanding of the potential for use of HTA in this context, an analytical framework was developed to describe and classify existing fourth hurdle systems...
  6. ncbi Cost-effectiveness of oral ibandronate versus IV zoledronic acid or IV pamidronate for bone metastases in patients receiving oral hormonal therapy for breast cancer in the United Kingdom
    Erwin De Cock
    The MEDTAP Institute at UBC, London, UK
    Clin Ther 27:1295-310. 2005
    ..Oral ibandronate is a single-nitrogen bisphosphonate whose efficacy is similar to that of IV ibandronate for the treatment of bone metastases...
  7. ncbi Selecting methods for the prediction of future events in cost-effectiveness models: a decision-framework and example from the cardiovascular field
    Richard Grieve
    Health Services Research Unit, Department of Public Health and Policy, London School of Hygiene and Tropical Medicine, Keppel Street, London, WC1E 7HT, UK
    Health Policy 64:311-24. 2003
    ..Such transparency can help decision-makers understand the scientific basis underpinning models, and therefore make these models more acceptable and useful for health policy-making...
  8. ncbi Regulating the economic evaluation of pharmaceuticals and medical devices: a European perspective
    Richard Cookson
    School of Medicine, Health Policy and Practice, University of East Anglia, Norwich Norfolk, NR4 7TJ, UK
    Health Policy 63:167-78. 2003
    ..negotiation of price-performance deals to facilitate the use of economic evidence in post-launch pricing review decisions, as information is gathered from studies of product performance in routine use...
  9. ncbi Developing the revised NICE appraisal technical guidance to manufacturers and sponsors: opportunity or threat?
    Rod S Taylor
    Department of Epidemiology and Public Health, University of Birmingham, Birmingham, United Kingdom
    Pharmacoeconomics 20:1031-8. 2002
    ..The lessons learnt from revision of the NICE guidance for manufacturers and sponsors and some main issues for its future development are discussed...
  10. ncbi Re: Detourney, B. The value of economic modeling studies in the evaluation of treatment strategies for multiple sclerosis. (Editorial) Value Health 2002;5:1-2
    John Hutton
    Value Health 5:114-5. 2002
  11. ncbi Use of economic evaluation in decision making: what needs to change?
    John Hutton
    Value Health 5:65-6. 2002